# [Pharmacy Curriculum: Platinum-Based Anticancer Agents]

## Key Concepts

* **Cisplatin**: A platinum-based anticancer agent used to treat various types of cancer, including non-Hodgkin's lymphoma, bladder cancer, ovarian cancer, and testicular cancer.
	+ Metabolized through aquation, resulting in the formation of reactive intermediates that bind to DNA.
	+ Adverse effects include dose-limiting myelosuppression, nausea, vomiting, and pulmonary symptoms such as interstitial pulmonary fibrosis (also known as "busulfan lung").
* **Carboplatin**: A platinum-based anticancer agent used to treat various types of cancer, including ovarian cancer, bladder cancer, germ cell tumors, head and neck cancers, small cell lung cancer, and NSCLC.
	+ Activation occurs through aquation, similar to cisplatin, but with slower binding to plasma proteins due to its greater stability.
	+ Adverse effects include myelosuppression, nausea, vomiting, and peripheral neuropathy.
* **Oxaliplatin**: A platinum-based anticancer agent used to treat various types of cancer, including ovarian cancer, metastatic colorectal cancer, and early stage colon cancer in combination with 5-fluorouracil/leucovorin.
	+ Activation occurs through aquation in low-chloride environments, resulting in the formation of reactive intermediates that bind to DNA.
	+ Adverse effects include neurotoxicity, nausea, vomiting, diarrhea, myelosuppression, and hypersensitivity reactions.

## Summary

* Platinum-based anticancer agents are used to treat various types of cancer, including non-Hodgkin's lymphoma, bladder cancer, ovarian cancer, testicular cancer, and others.
* Adverse effects include dose-limiting myelosuppression, nausea, vomiting, pulmonary symptoms, neurotoxicity, and renal toxicity.

## Important Information

* Cisplatin is the most reactive platinum-based anticancer agent, resulting in significant toxicities compared to other platins.
* Carboplatin has a slower binding rate to plasma proteins due to its greater stability, reducing nephrotoxicity compared to cisplatin.
* Oxaliplatin does not show cross-resistance with cisplatin and is not recognized by MMR enzymes.

# [استراتيجيات تصميم الأدوية]
## المفاهيم الرئيسية

* **سيسبلاتين**: مادة دوائيةBased platinum-based anticancer agent used to treat various types of cancer, including non-Hodgkin's lymphoma, bladder cancer, ovarian cancer, and testicular cancer.
	+ تتم تحلل المادة بواسطة aquation، مما يؤدي إلى形成 intermediate reaktif التي تربط مع DNA.
	+ الأعراض السلبية تتضمن الحدّ 限 myelosuppression، nausea، vomiting، وآلام رئوية مثل "busulfan lung".
* **كاربوبلاتين**: مادة دوائيةBased platinum-based anticancer agent used to treat various types of cancer, including ovarian cancer, bladder cancer, germ cell tumors, head and neck cancers, small cell lung cancer, and NSCLC.
	+ تتم تحلل المادة بواسطة aquation، مما يؤدي إلى形成 intermediate reaktif التي تربط مع DNA.
	+ الأعراض السلبية تتضمن الحدّ 限 myelosuppression، nausea، vomiting، وآلام لateral neuropathy.
* **أوكسيلباتين**: مادة دوائيةBased platinum-based anticancer agent used to treat various types of cancer, including ovarian cancer, metastatic colorectal cancer, and early stage colon cancer in combination with 5-fluorouracil/leucovorin.
	+ تتم تحلل المادة بواسطة aquation في البيئة منخفضة الكلوريد، مما يؤدي إلى形成 intermediate reaktif التي تربط مع DNA.
	+ الأعراض السلبية تتضمن neurotoxicity، nausea، vomiting، diarrhea، myelosuppression، and hypersensitivity reactions.

## ملخص

* المادتان platinum-based anticancer agents مستخدمة في علاج مختلف أنواع السرطان، بما في ذلك lymphoma غير Hodgkin's، cancer of the bladder، cancer of the ovaries، cancer of the testicles، وغيرها.
* الأعراض السلبية تتضمن الحدّ 限 myelosuppression، nausea، vomiting، pulmonary symptoms، neurotoxicity، and renal toxicity.

## معلومات مهمة

* سيسبلاتين هو الأكثر تحركاً platinum-based anticancer agent، مما يؤدي إلى آلاج significant toxicities Compared to other platins.
* كاربوبلاتين لديه скорость ارتباط أبطأ مع بروتينات البلازما بسبب استقراره أكبر، مما يقلل nephrotoxicity Compared to سيسبلاتين.
* أوكسيلباتين لا يظهر cross-resistance مع سيسبلاتين ولا يعترف به من قبل enzymes MMR.